<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study was to present our diagnostic and therapeutic experience with antiphospholipide syndrome (APS) and vascular <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Ninety-nine patients with positive antiphospholipide antibodies (aPL) and vascular <z:mp ids='MP_0005048'>thrombosis</z:mp> were included in the study: forty patients, according to clinical classification criteria, had primary antiphospholipide syndrome (PAPS), and fifty-nine patients had secondary antiphospholipide syndrome (SAPS) </plain></SENT>
<SENT sid="2" pm="."><plain>In PAPS group, 82.5% of the patients were LA-positive, 37.5% of the patients were IgG aCL-positive, 27.5% of the patients were IgM aCL-positive, and 15% of the patients were IgG antibeta2GPI-positive </plain></SENT>
<SENT sid="3" pm="."><plain>In SAPS group, 61% of the patients were LA-positive, 50.8% of the patients were IgG aCL-positive, and 47.5% of the patients were IgM aCL-positive </plain></SENT>
<SENT sid="4" pm="."><plain>Administered therapy was low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> (LMWH) throughout 7 days, followed by <z:chebi fb="8" ids="10033">warfarin</z:chebi> with prothrombin time maintained between 2.0 and 3.0 INR </plain></SENT>
</text></document>